COMPANY PROFILE

Kairuibiotech

Explore full profile

The originator of international serum-free cell culture technology,

ChinaFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Kairuibiotech

Kairuibiotech operates as a developer and manufacturer specializing in serum-free media for mammalian cell cultures. The company's core business revolves around creating and optimizing these specialized products to meet client demands while also introducing new solutions to the market. Based in Zhuhai, China, the firm is positioned within the biotechnology and pharmaceutical outsourcing services sector.

The company's primary offering is a serum-free cell culture product designed for various applications within the life sciences. This positions Kairuibiotech as a key supplier for research institutions, pharmaceutical companies, and other entities that rely on cell culture technology. The business model appears to be direct sales of these manufactured goods. The company has successfully secured funding, including a notable Later Stage VC (Series A) round on November 1, 2022, which raised $13.9 million, indicating it is in a revenue-generating stage.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: China
Open positions: None listed
Dealroom signal: 21.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Nov 2022	$14M	$55M	Dingsheng Technology · Yanghe Investment · Juke Investment · Guangzhou Jet Biofiltration	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Kairuibiotech website traffic

Latest recorded traffic for Kairuibiotech is 320 monthly website visits, up 100% over the last three months.

Latest monthly visits320 3-month web change+100%

Monthly website visitsOct 2022–Apr 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
RBResilient BioticsDeveloping microbiome therapies and using data science for therapeutic discovery	Durham, United States	Operational	10	$7.1M	$28M
CSCarevive SystemsProviding personalized and dynamic cancer care plans for patients	North Miami Beach, United States	Acquired
BBBiond BiologicsInnovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients	Misgav Am, Israel	Operational
RTRTsafeEnsures safety and efficiency of radiation oncology treatments of cancer patients, in a personalized (patient-specific) manner	Athens, Greece	Operational
CICiloaDedicated to the production of fully native membrane proteins on exosomes	Montpellier, France	Operational
ANAnnoroadA leading developer and marketer on genomic innovation technologies for research and clinical market	Dongcheng District, China	Operational
LHLegacy HealthcareBiopharma developing innovative botanical drugs in supportive oncology care and dermatology	Epalinges, Switzerland	Operational
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational